Biguanide Market
Biguanide Market Size, Share & Trends Analysis Report, By Product Type (Metformin IR, Metformin ER, Phenformin, Buformin, Polyhexamethylene Biguanide), By Drug Form (Oral Tablets, Oral Solutions, Topical Formulations), Forecast Period (2026–2035)
Industry Overview
Biguanide market was valued at $5.8 billion in 2025 and is projected to reach $8.1 billion by 2035, growing at a CAGR of 3.5% during 2026 to 2035. Biguanides, primarily dominated by metformin-based formulations, represent one of the most widely prescribed therapeutic classes globally for diabetes management. According to the World Health Organization (WHO), over 830 million people globally are living with diabetes, with type 2 diabetes accounting for approximately 90% of cases, significantly driving demand for metformin-based drugs.
Additionally, data from the International Diabetes Federation (IDF) suggests that global diabetes prevalence is expected to reach nearly 643 million by 2030, reinforcing long-term demand stability. Beyond pharmaceuticals, Polyhexamethylene biguanide (PHMB) is witnessing increased usage in wound care, disinfectants, and water treatment, expanding the market scope. The market is characterized by high generic penetration, cost-driven competition, and strong regulatory oversight, especially from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Market Dynamics
Rising Global Diabetes Burden Driving Metformin Demand
The increasing prevalence of diabetes is the primary growth driver for the biguanide market. According to the World Health Organization (WHO), diabetes is among the top ten causes of death globally, with over 1.5 million deaths annually directly attributed to the disease. The International Diabetes Federation (IDF) further highlights that healthcare spending on diabetes exceeded $960 billion globally in 2021, indicating strong and sustained demand for cost-effective treatments such as metformin.
Metformin remains the first-line therapy recommended by major clinical guidelines due to its efficacy, affordability, and safety profile. Pharmaceutical companies are actively expanding production capacities and optimizing supply chains to meet rising demand, particularly in emerging markets such as India and China. Additionally, the increasing adoption of extended-release (ER) formulations is improving patient compliance, further boosting market growth.
Pricing Pressure and Generic Market Saturation
Despite stable demand, the biguanide market faces significant challenges due to intense price competition and market commoditization. The dominance of generic manufacturers has led to continuous price erosion, particularly in developed markets. According to the OECD, generic medicines account for over 70% of pharmaceutical volume consumption in several developed countries, placing downward pressure on margins.
Supply chain disruptions, particularly in active pharmaceutical ingredient (API) sourcing, have also impacted production stability. A significant portion of metformin API production is concentrated in Asia, increasing vulnerability to geopolitical and logistical risks. Additionally, regulatory scrutiny from agencies like the U.S. FDA regarding impurities in metformin products has led to recalls and increased compliance costs. To counter these challenges, companies are focusing on cost optimization, vertical integration, and diversification into PHMB-based applications, which offer relatively higher margins.
Market Segmentation
- Based on the product type, the market is segmented into metformin IR, metformin ER, phenformin, buformin, and Polyhexamethylene biguanide (PHMB).
- Based on the drug form, the market is segmented into oral tablets, oral solutions, and topical formulations (PHMB-based).
Metformin Segment Leads the Market
The metformin (IR and ER) segment dominates the global biguanide market, accounting for the majority of total revenue share. This dominance is driven by its widespread use as a first-line treatment for type 2 diabetes across global healthcare systems. The WHO Essential Medicines List includes metformin, further reinforcing its universal adoption. Between 2022 and 2026, pharmaceutical companies have focused on expanding production capacity and improving formulation efficiency. The introduction of extended-release (ER) variants has improved patient adherence and minimized gastrointestinal side effects, increasing prescription rates. Emerging economies continue to drive volume growth due to expanding healthcare access and government-led diabetes management programs.
PHMB Segment to Record Strong Growth
The Polyhexamethylene biguanide (PHMB) segment is expected to witness the fastest growth during the forecast period. This growth is attributed to its increasing application in wound care, disinfectants, and water treatment systems. The European Centre for Disease Prevention and Control (ECDC) has emphasized the growing need for effective antimicrobial agents, supporting PHMB adoption. Technological advancements in antimicrobial formulations and the rising demand for hygiene products post-pandemic have further accelerated market expansion. Investments in healthcare infrastructure and infection control practices, particularly in developing regions, are creating new growth opportunities for PHMB manufacturers.
Regional Outlook
The global biguanide market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the biguanide market due to its large diabetic population and advanced healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes, driving substantial demand for metformin-based therapies. The presence of major pharmaceutical companies and strong regulatory frameworks further supports market growth. Additionally, high healthcare expenditure, exceeding $4.5 trillion annually (as per CMS), ensures sustained access to essential medications.
India to Record Strong Growth
India is expected to witness the fastest growth in the biguanide market. The World Health Organization (WHO) estimates that India has over 77 million diabetic patients, making it one of the largest diabetes markets globally. Rapid urbanization, lifestyle changes, and increasing healthcare awareness are contributing to the rising demand. The Indian pharmaceutical industry, supported by organizations such as the Indian Brand Equity Foundation (IBEF), is a major global supplier of generic drugs, including metformin. Expansion in manufacturing capacity and export-oriented growth strategies are further strengthening the country’s position in the global market.
Market Player Outlook
The global biguanide market is highly competitive and fragmented, characterized by the presence of numerous generic drug manufacturers and specialty chemical companies. Key players such as Merck KGaA, Sanofi, Bristol-Myers Squibb, Teva Pharmaceutical Industries, and Sun Pharmaceutical Industries play a significant role in shaping the market landscape. Companies are focusing on cost leadership, portfolio expansion, and geographic diversification to maintain competitiveness. Strategic investments in manufacturing capabilities and regulatory compliance are critical to sustaining market share.
Recent Developments
- In April 2026, Aurobindo Pharma Limited strengthened its position in the Biguanide market with S. Food and Drug Administration approval for its dapagliflozin and metformin hydrochloride extended-release tablets. This AB-rated generic equivalent to Xigduo XR enhances the company’s diabetes portfolio and expands its presence in combination therapies.
- In April 2026, Lupin Limited strengthened its presence in the Biguanide and broader anti-diabetic market through the U.S. launch of Dapagliflozin tablets, following regulatory approval from the S. Food and Drug Administration. Although Dapagliflozin belongs to the SGLT2 inhibitor class, this moves complements Lupin’s diabetes portfolio, enhancing its competitive positioning alongside Biguanide therapies such as metformin.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global biguanide market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Biguanide Market Sales Analysis – Product Type | Drug Form ($ Million)
- Biguanide Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Biguanide Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Biguanide Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Biguanide Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Biguanide Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Biguanide Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Biguanide Market Revenue and Share by Manufacturers
- Biguanide Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 Merck KGaA
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Sanofi
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Bristol-Myers Squibb
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Teva Pharmaceutical Industries
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Sun Pharmaceutical Industries
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Biguanide Market Sales Analysis by Product Type ($ Million)
5.1 Metformin IR
5.2 Metformin ER
5.3 Phenformin
5.4 Buformin
5.5 Polyhexamethylene Biguanide (PHMB)
- Global Biguanide Market Sales Analysis by Drug Form ($ Million)
6.1 Oral Tablets
6.2 Oral Solutions
6.3 Topical Formulations (PHMB-based)
- Regional Analysis
7.1 North American Biguanide Market Sales Analysis – Product Type | Drug Form | Country ($ Million)
7.1.1 United States
7.1.2 Canada
7.2 European Biguanide Market Sales Analysis – Product Type | Drug Form | Country ($ Million)
7.2.1 UK
7.2.2 Germany
7.2.3 Italy
7.2.4 Spain
7.2.5 France
7.2.6 Russia
7.2.7 Rest of Europe
7.3 Asia-Pacific Biguanide Market Sales Analysis – Product Type | Drug Form | Country ($ Million)
7.3.1 China
7.3.2 Japan
7.3.3 South Korea
7.3.4 India
7.3.5 Australia & New Zealand
7.3.6 ASEAN Countries
7.3.7 Rest of Asia-Pacific
7.4 Rest of the World Biguanide Market Sales Analysis – Product Type | Drug Form | Country ($ Million)
7.4.1 Latin America
7.4.2 Middle East and Africa
- Company Profiles
8.1 Alkem Laboratories Ltd.
8.1.1 Quick Facts
8.1.2 Company Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.2 Abhilasha Pharma
8.2.1 Quick Facts
8.2.2 Company Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
8.3 Apotex Inc.
8.3.1 Quick Facts
8.3.2 Company Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.4 Aurobindo Pharma
8.4.1 Quick Facts
8.4.2 Company Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.5 Bristol-Myers Squibb
8.5.1 Quick Facts
8.5.2 Company Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.6 Cipla
8.6.1 Quick Facts
8.6.2 Company Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.7 Dr. Reddy’s Laboratories
8.7.1 Quick Facts
8.7.2 Company Overview
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.8 Garonit Pharmaceutical
8.8.1 Quick Facts
8.8.2 Company Overview
8.8.3 Product Portfolio
8.8.4 Business Strategies
8.9 Granules India
8.9.1 Quick Facts
8.9.2 Company Overview
8.9.3 Product Portfolio
8.9.4 Business Strategies
8.10 Laboratoire Pareva
8.10.1 Quick Facts
8.10.2 Company Overview
8.10.3 Product Portfolio
8.10.4 Business Strategies
8.11 Lonza
8.11.1 Quick Facts
8.11.2 Company Overview
8.11.3 Product Portfolio
8.11.4 Business Strategies
8.12 Lupin Limited
8.12.1 Quick Facts
8.12.2 Company Overview
8.12.3 Product Portfolio
8.12.4 Business Strategies
8.13 Merck KGaA
8.13.1 Quick Facts
8.13.2 Company Overview
8.13.3 Product Portfolio
8.13.4 Business Strategies
8.14 Sandoz (Novartis)
8.14.1 Quick Facts
8.14.2 Company Overview
8.14.3 Product Portfolio
8.14.4 Business Strategies
8.15 Sanofi
8.15.1 Quick Facts
8.15.2 Company Overview
8.15.3 Product Portfolio
8.15.4 Business Strategies
8.16 Strides Pharma
8.16.1 Quick Facts
8.16.2 Company Overview
8.16.3 Product Portfolio
8.16.4 Business Strategies
8.17 Sun Pharmaceutical Industries
8.17.1 Quick Facts
8.17.2 Company Overview
8.17.3 Product Portfolio
8.17.4 Business Strategies
8.18 Teva Pharmaceutical Industries
8.18.1 Quick Facts
8.18.2 Company Overview
8.18.3 Product Portfolio
8.18.4 Business Strategies
8.19 Thor Group
8.19.1 Quick Facts
8.19.2 Company Overview
8.19.3 Product Portfolio
8.19.4 Business Strategies
8.20 Torrent Pharmaceuticals
8.20.1 Quick Facts
8.20.2 Company Overview
8.20.3 Product Portfolio
8.20.4 Business Strategies
8.21 Viatris (Mylan)
8.21.1 Quick Facts
8.21.2 Company Overview
8.21.3 Product Portfolio
8.21.4 Business Strategies
8.22 Wanbury Limited
8.22.1 Quick Facts
8.22.2 Company Overview
8.22.3 Product Portfolio
8.22.4 Business Strategies
8.23 Zydus Lifesciences
8.23.1 Quick Facts
8.23.2 Company Overview
8.23.3 Product Portfolio
8.23.4 Business Strategies
1. Global Biguanide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Global Metformin IR Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Metformin ER Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Phenformin Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Buformin Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Polyhexamethylene Biguanide (PHMB) Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Biguanide Market Research and Analysis by Drug Form, 2025–2035 ($ Million)
8. Global Oral Tablets Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Oral Solutions Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Topical Formulations (PHMB-based) Biguanide Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Biguanide Market by Region, 2025–2035 ($ Million)
12. North America Biguanide Market Research and Analysis by Country, 2025–2035 ($ Million)
13. North America Biguanide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
14. North America Biguanide Market Research and Analysis by Drug Form, 2025–2035 ($ Million)
15. Europe Biguanide Market Research and Analysis by Country, 2025–2035 ($ Million)
16. Europe Biguanide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
17. Europe Biguanide Market Research and Analysis by Drug Form, 2025–2035 ($ Million)
18. Asia-Pacific Biguanide Market Research and Analysis by Country, 2025–2035 ($ Million)
19. Asia-Pacific Biguanide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
20. Asia-Pacific Biguanide Market Research and Analysis by Drug Form, 2025–2035 ($ Million)
21. Rest of the World Biguanide Market Research and Analysis by Country, 2025–2035 ($ Million)
22. Rest of the World Biguanide Market Research and Analysis by Product Type, 2025–2035 ($ Million)
23. Rest of the World Biguanide Market Research and Analysis by Drug Form, 2025–2035 ($ Million)
1. Global Biguanide Market Share by Product Type, 2025 Vs 2035 (%)
2. Global Metformin IR Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
3. Global Metformin ER Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
4. Global Phenformin Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
5. Global Buformin Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
6. Global Polyhexamethylene Biguanide (PHMB) Market Research and Analysis by Region, 2025 Vs 2035 (%)
7. Global Biguanide Market Share by Drug Form, 2025 Vs 2035 (%)
8. Global Oral Tablets Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
9. Global Oral Solutions Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
10. Global Topical Formulations (PHMB-based) Biguanide Market Research and Analysis by Region, 2025 Vs 2035 (%)
11. Global Biguanide Market Share by Region, 2025-2035 ($ Million)
12. United States Biguanide Market Size, 2025-2035 ($ Million)
13. Canada Biguanide Market Size, 2025-2035 ($ Million)
14. UK Biguanide Market Size, 2025-2035 ($ Million)
15. France Biguanide Market Size, 2025-2035 ($ Million)
16. Germany Biguanide Market Size, 2025-2035 ($ Million)
17. Italy Biguanide Market Size, 2025-2035 ($ Million)
18. Spain Biguanide Market Size, 2025-2035 ($ Million)
19. Russia Biguanide Market Size, 2025-2035 ($ Million)
20. India Biguanide Market Size, 2025-2035 ($ Million)
21. China Biguanide Market Size, 2025-2035 ($ Million
22. Japan Biguanide Market Size, 2025-2035 ($ Million
23. South Korea Biguanide Market Size, 2025-2035 ($ Million)
24. Australia & New Zealand Biguanide Market Size, 2025-2035 ($ Million)
25. ASEAN Biguanide Market Size, 2025-2035 ($ Million)
26. Rest of Asia-Pacific Biguanide Market Size, 2025-2035 ($ Million)
27. Latin America Biguanide Market Size, 2025-2035 ($ Million)
28. Middle East & Africa Biguanide Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
